Adjusted EBITDA Margin Maintained
Delivered adjusted EBITDA of $5.3 million and an adjusted EBITDA margin of 9% for the quarter, demonstrating margin resilience despite lower revenue.
Positive Free Cash Flow
Generated approximately $3.8 million of free cash flow in the quarter, supporting liquidity and deleveraging efforts.
Debt Reduction and Deleveraging Resumed
Total debt reduced to $132.7 million from $136.6 million the prior quarter (a reduction of ~$3.9 million, ~2.9%), with management expecting to convert ~50%–55% of fiscal 2026 EBITDA toward debt reduction by year-end and remaining in compliance with financial covenants.
Two-Year NIH Sole-Source Extension
Awarded a two-year sole-source extension to continue providing clinical research support services to the National Institutes of Health, adding short-term revenue visibility in the public health portfolio.
Improving Federal Funding Environment and Pipeline
Management highlighted that FY2026 budget outcomes and FY2027 requests show increased funding for defense/intelligence and some federal health agencies, improved procurement clarity, accelerating solicitations, and a healthy pipeline with multiple delayed procurements now coming to bid.
Recognition for Technology and Program Performance
Recent industry and customer recognitions for projects in automation, AI, scientific research, data science, and IT underline DLH's technical capabilities and differentiators (Cyclone, Nexus Labs digital sandbox).
Operational Right-Sizing Completed
Company implemented cost-scaling and right-sizing initiatives in Q2; management indicates the material reductions needed to align cost structure with near-term revenue have been achieved, with ongoing evaluation of leases and footprint.